Offerings include RNA, MicroRNA and DNA based molecular diagnostic products providing identification of genetic abnormalities associated with oncology and genetic diseases.
•
Winkler then formed Asuragen from Ambion's Molecular Diagnostics and Pharmacogenomic Service Divisions following the March 2006 sale of the Research Products Division of Ambion Inc. to the Applied Biosystems Group (currently Life Technologies).